 LATAM is a report based on a new study conducted amongst approximately 116 Type 2 (T2D) diabetes patients in Brazil and 105 patients in Mexico. The study comprised of 30-minute quantitative online and qualitative telephone interviews with T2D patients.

	The LATAM report is intended to help pharmaceutical companies developing products in diabetes in this region to gain a deeper understanding of how patients come to be diagnosed with it and how it impacts their day-to-day lives physically, emotionally and socially. It also explores patient attitudes and perceptions towards treatment, the healthcare professionals managing their condition, as well as identifying the types of support and education patients need at key stages of their journey.

, Mariel Metcalfe commented, “With an increase in prevalence to 14% of the population in Mexico and 9% of the population in Brazil, diabetes is now one of the leading causes of mortality and disability in Latin America. This report provides comprehensive, quantitative insights into patient behaviours, perceptions and needs, as well as their feelings at key stages of their journey living with Type 2 Diabetes.”

	Currently being conducted in LATAM but looking to expand the survey to the US, EU and Asia, Living with Diabetes is just one in a series of reports offering comprehensive insight into the chronic disease patient journey from pre-diagnosis to stabilisation. The Living with 

 (EU & US) reports are published and available to purchase. 
	
	Living with 

 - NASH (EU) reports will be launched in the 1st quarter of 2019.

	More detailed findings from the study can be provided from Mariel Metcalfe on 